Week In Review: BeiGene Signs $2.2 Billion Deal With Novartis For PD-1

Beijing's BeiGene out-licensed ex-China rights for tislelizumab, its anti-PD-1 antibody, to Novartis​​​ in a $2.2 billion agreement. The deal includes a $650 million upfront payment to BeiGene, plus up to $1.3 billion in regulatory milestones.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.